Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.

Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK.

J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304. [Epub ahead of print]

PMID:
31461380
2.

Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141].

Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V.

Lung Cancer. 2019 Aug 21. pii: S0169-5002(19)30618-X. doi: 10.1016/j.lungcan.2019.08.017. [Epub ahead of print] No abstract available.

PMID:
31445783
3.

Variation in Technical Quality of Breast MRI.

Ruiz-Flores L, Whitman GJ, Le-Petross HTC, Hess KR, Parikh JR.

Acad Radiol. 2019 Jul 29. pii: S1076-6332(19)30332-0. doi: 10.1016/j.acra.2019.07.002. [Epub ahead of print]

PMID:
31371208
4.

Imaging Follow-up Versus Surgical Excision for Radial Scars Identified on Tomosynthesis-Guided Core Needle Biopsy.

Martaindale S, Omofoye TS, Teichgraeber DC, Hess KR, Whitman GJ.

Acad Radiol. 2019 Jul 13. pii: S1076-6332(19)30302-2. doi: 10.1016/j.acra.2019.05.012. [Epub ahead of print]

PMID:
31311772
5.

Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center.

Asare EA, Silva-Figueroa A, Hess KR, Busaidy N, Graham PH, Grubbs EG, Lee JE, Williams MD, Perrier ND.

Ann Surg Oncol. 2019 Oct;26(11):3593-3599. doi: 10.1245/s10434-019-07451-3. Epub 2019 May 20.

PMID:
31111352
6.

Not all patients with a diagnosis of a radial scar require excision.

Eghtedari M, Le-Petross H, Babiera GV, Albarracin CT, Hess KR, Woodtichartpreecha P, Whitman GJ.

Breast J. 2019 Jul;25(4):792-794. doi: 10.1111/tbj.13329. Epub 2019 May 13. No abstract available.

PMID:
31087426
7.

Immediate Migration of Biopsy Clip Markers After Upright Digital Breast Tomosynthesis-Guided Vacuum-Assisted Core Biopsy.

Teichgraeber DC, Martaindale S, Omofoye TS, Hess KR, Parikh JR, Whitman GJ.

Acad Radiol. 2019 May 7. pii: S1076-6332(19)30181-3. doi: 10.1016/j.acra.2019.03.022. [Epub ahead of print]

PMID:
31076332
8.

Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).

Baez-Vallecillo L, Raghavendra AS, Hess KR, Barcenas CH, Moulder SL, Tripathy D, Valero V, Murthy RK.

Breast Cancer Res Treat. 2019 Jul;176(1):227-234. doi: 10.1007/s10549-018-05081-z. Epub 2019 Apr 11.

PMID:
30977027
9.

Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAFV600-Mutant Stage III Melanoma Seems to be Short-Lived.

Hess KR.

J Clin Oncol. 2019 May 20;37(15):1354-1355. doi: 10.1200/JCO.18.01768. Epub 2019 Apr 2. No abstract available.

PMID:
30939097
10.

Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study.

George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS.

J Med Internet Res. 2019 Mar 14;21(3):e10348. doi: 10.2196/10348.

11.

Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.

Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS.

Oncotarget. 2019 Jan 29;10(9):1011-1013. doi: 10.18632/oncotarget.26658. eCollection 2019 Jan 29.

12.

Minimally Invasive Cordotomy for Refractory Cancer Pain: A Randomized Controlled Trial.

Viswanathan A, Vedantam A, Hess KR, Ochoa J, Dougherty PM, Reddy AS, Koyyalagunta D, Reddy S, Bruera E.

Oncologist. 2019 Jul;24(7):e590-e596. doi: 10.1634/theoncologist.2018-0570. Epub 2019 Feb 22.

PMID:
30796153
13.

Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.

Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E.

Clin Cancer Res. 2019 Jul 1;25(13):3802-3810. doi: 10.1158/1078-0432.CCR-18-3964. Epub 2019 Feb 7.

PMID:
30733229
14.

Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center.

George GC, Buford A, Hess K, Piha-Paul SA, Zinner R, Subbiah V, Hinojosa C, Cleeland CS, Meric-Bernstam F, Bernstam EV, Hong DS.

JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00030.

15.

Correction to: Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy.

Beechar VB, Prabhu SS, Bastos D, Weinberg JS, Stafford RJ, Fuentes D, Hess KR, Rao G.

J Neurooncol. 2019 Jan;141(2):475. doi: 10.1007/s11060-019-03093-3.

PMID:
30635762
16.

Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.

Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V.

Invest New Drugs. 2019 Apr;37(2):345-351. doi: 10.1007/s10637-018-0700-z. Epub 2019 Jan 5.

PMID:
30610588
17.

Moving Precision Oncology Forward Amid Myths and Misconceptions.

Janku F, Hess KR, Yap TA.

JAMA Oncol. 2018 Dec 1;4(12):1788-1789. doi: 10.1001/jamaoncol.2018.5064. No abstract available.

PMID:
30419079
18.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.

Cancer. 2019 Feb 1;125(3):424-433. doi: 10.1002/cncr.31811. Epub 2018 Oct 25. Erratum in: Cancer. 2019 Apr 15;125(8):1387.

PMID:
30359477
19.

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer.

Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S.

Oncotarget. 2018 Sep 7;9(70):33258-33270. doi: 10.18632/oncotarget.25947. eCollection 2018 Sep 7.

20.

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS.

Oncotarget. 2018 Sep 4;9(69):33232-33243. doi: 10.18632/oncotarget.26075. eCollection 2018 Sep 4.

21.

Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.

Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K.

Clin Cancer Res. 2018 Dec 15;24(24):6594-6610. doi: 10.1158/1078-0432.CCR-18-1446. Epub 2018 Sep 4.

PMID:
30181387
22.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL.

Oncologist. 2018 Nov;23(11):1300-1309. doi: 10.1634/theoncologist.2017-0498. Epub 2018 Aug 23.

PMID:
30139837
23.

Sex as a predictor of response to cancer immunotherapy.

McQuade JL, Daniel CR, Hess KR, Davies MA.

Lancet Oncol. 2018 Aug;19(8):e376. doi: 10.1016/S1470-2045(18)30483-2. No abstract available.

PMID:
30102226
24.

Phase 1 Study of Spinal Cord Constraint Relaxation With Single Session Spine Stereotactic Radiosurgery in the Primary Management of Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression.

Ghia AJ, Guha-Thakurta N, Hess K, Yang JN, Settle SH, Sharpe HJ, Li J, McAleer M, Chang EL, Tatsui CE, Brown PD, Rhines LD.

Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1481-1488. doi: 10.1016/j.ijrobp.2018.07.2023. Epub 2018 Aug 9.

PMID:
30099131
25.

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT.

Clin Breast Cancer. 2018 Dec;18(6):e1283-e1288. doi: 10.1016/j.clbc.2018.07.008. Epub 2018 Jul 10.

PMID:
30077429
26.

Imaging of Intracystic Papillary Carcinoma.

Speer ME, Adrada BE, Arribas EM, Hess KR, Middleton LP, Whitman GJ.

Curr Probl Diagn Radiol. 2019 Jul - Aug;48(4):348-352. doi: 10.1067/j.cpradiol.2018.05.001. Epub 2018 May 22.

PMID:
30072190
27.

Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review.

Gupta V, Coburn N, Kidane B, Hess KR, Compton C, Ringash J, Darling G, Mahar AL.

J Thorac Cardiovasc Surg. 2018 Aug;156(2):847-856. doi: 10.1016/j.jtcvs.2018.03.146. Epub 2018 Apr 12.

PMID:
30011772
28.

Somatotopy and Organization of Spinothalamic Tracts in the Human Cervical Spinal Cord.

Vedantam A, Bruera E, Hess KR, Dougherty PM, Viswanathan A.

Neurosurgery. 2019 Jun 1;84(6):E311-E317. doi: 10.1093/neuros/nyy330.

PMID:
30011044
29.

High risk breast lesions identified on MRI-guided vacuum-assisted needle biopsy: outcome of surgical excision and imaging follow-up.

Speer ME, Huang ML, Dogan BE, Adrada BE, Candelaria RP, Hess KR, Hansakul P, Yang WT, Rauch GM.

Br J Radiol. 2018 Oct;91(1090):20180300. doi: 10.1259/bjr.20180300. Epub 2018 Jul 5.

PMID:
29947265
30.

An effort expenditure perspective on cancer-related fatigue.

Lacourt TE, Vichaya EG, Escalante C, Manzullo EF, Gunn B, Hess KR, Heijnen CJ, Dantzer R.

Psychoneuroendocrinology. 2018 Oct;96:109-117. doi: 10.1016/j.psyneuen.2018.06.009. Epub 2018 Jun 9.

PMID:
29929087
31.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

PMID:
29848573
32.

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.

Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V.

Lung Cancer. 2018 Jun;120:137-141. doi: 10.1016/j.lungcan.2018.03.020. Epub 2018 Apr 11. Erratum in: Lung Cancer. 2019 Aug 21;:.

33.

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.

Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D.

Br J Cancer. 2018 May;118(11):1419-1424. doi: 10.1038/s41416-018-0068-z. Epub 2018 Apr 26.

34.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

35.
36.

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK.

Cancer. 2018 Jun 1;124(11):2299-2305. doi: 10.1002/cncr.31336. Epub 2018 Mar 26.

37.

The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium.

Hui D, Hess K, Dibaj SS, Arthur J, Dev R, Dalal S, Reddy S, Bruera E.

Cancer. 2018 May 15;124(10):2246-2252. doi: 10.1002/cncr.31312. Epub 2018 Feb 22.

38.

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.

Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V.

Br J Cancer. 2018 Mar 20;118(6):763-769. doi: 10.1038/bjc.2017.480. Epub 2018 Feb 20.

39.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.

Lancet Oncol. 2018 Mar;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12.

40.

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.

Levin VA, Ictech SE, Hess KR.

CNS Oncol. 2018 Apr;7(2):CNS16. doi: 10.2217/cns-2017-0031. Epub 2018 Jan 30. Review.

41.

Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies.

Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L.

JAMA Oncol. 2018 Apr 12;4(4):e175092. doi: 10.1001/jamaoncol.2017.5092. Epub 2018 Apr 12.

42.

Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery.

Jensen G, Tang C, Hess KR, Bishop AJ, Pan HY, Li J, Yang JN, Tannir NM, Amini B, Tatsui C, Rhines L, Brown PD, Ghia AJ.

J Radiosurg SBRT. 2017;5(1):25-34.

43.

Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.

Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00259. Epub 2018 Jun 14.

44.

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V.

J Immunother Cancer. 2017 Dec 19;5(1):100. doi: 10.1186/s40425-017-0301-y.

45.

Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy.

Beechar VB, Prabhu SS, Bastos D, Weinberg JS, Stafford RJ, Fuentes D, Hess KR, Rao G.

J Neurooncol. 2018 Mar;137(1):57-65. doi: 10.1007/s11060-017-2694-3. Epub 2017 Dec 4. Erratum in: J Neurooncol. 2019 Jan;141(2):475.

46.

A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma.

Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP.

Oncotarget. 2017 Oct 12;8(52):90488-90495. doi: 10.18632/oncotarget.21799. eCollection 2017 Oct 27.

47.

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.

Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.

Thyroid. 2018 Jan;28(1):79-87. doi: 10.1089/thy.2017.0285. Epub 2017 Dec 21.

48.

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):638-646. doi: 10.1007/s10637-017-0534-0. Epub 2017 Nov 21.

49.

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.

Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA.

Oncotarget. 2017 Aug 3;8(50):87163-87173. doi: 10.18632/oncotarget.19897. eCollection 2017 Oct 20.

50.

Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors.

Sen S, Meric-Bernstam F, Hong DS, Hess KR, Subbiah V.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx094.

Supplemental Content

Loading ...
Support Center